Hosted on MSN1mon
FDA beats EMA to most approved new drugs in 2024
The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in 2024. On 15 January, the two agencies ...
Hosted on MSN1mon
FDA protocol deviation guidance could go further
A protocol violation is a significant occurrence or event which may affect participant safety or the integrity of the research, or a consistent variation ... EMA guidance, but I have not seen FDA ...
pharmaphorum8y
FDA and EMA to work more closely on paediatric drug regulation
The FDA and EMA require all new drugs to have plans for paediatric development included in their file, unless companies can obtain waivers or deferrals. The plans can be worth big money to ...
pharmaphorum5d
After FDA snub, EMA backs FibroGen, Astellas' roxadustat
The EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease (CKD), just days after the FDA turned ... after the EMA's CHMP scientific ...
Business Insider1mon
Biogen announces FDA, EMA accepted applications for higher dose of nusinersen
Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has accepted the company’s supplemental New Drug Application, sNDA, and the European Medicines Agency, EMA, has validated ...
Yahoo Finance23d
IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
Kristina Torfgård. Following the successful dialogue with EMA and the company's prior End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), IRLAB has reached a consensus with ...